Trial Profile

Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP-T Combined Vaccine (PENTAXIM) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM) Given Simultaneously at Separate Sites With PRP-T Conjugate Vaccine (ACTHIB) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP poliovirus vaccine; Hib vaccine conjugate
Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics; Registrational
Sponsors Sanofi

01 Sep 2016 Results published in the Journal of Korean Medical Science
16 Apr 2012 Actual patient number is 370 according to ClinicalTrials.gov.
16 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com